Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2023-02-01 00:00:00 ET · period of report 2023-01-31 · accession 0001867096-23-000023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | 2023-01-31 | XERS | Edick Paul R | See Remarks, Dir | A - Grant | $0.00 | +750.0K | 2.28M | +49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-31 | A | A | 750,000 | $0.00 | 2,278,064 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. |